These innovative molecules represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://bushrabibb140634.frewwebs.com/39130830/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide